HomeAI · summaries
Storia in 2 fonti
Biotech Collapses Nearly 30% On A Nasty Surprise From CVS
ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray to its formulary.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage - ARS Pharma
SPRY stock drops after ARS says no new neffy coverage decisions in July formulary cycle.
- ·
investors.com
Biotech Collapses Nearly 30% On A Nasty Surprise From CVS
ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray to its formulary.
- ·
ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins - ARS Pharmaceuticals (
ARS Pharma reaffirmed its 2027 breakeven target, cut expenses and gained Florida Medicaid access for Neffy despite coverage setbacks.